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Abstract 
We have studied the effects of benextramine onthe U46619 (11 t~,9a-epoxymethano-15S-hydroxy-prosta-5Z, 13 E-dienoic acid)-media- 
ted contraction of the rat isolated small mesenteric artery. U46619 (10 nM-10 ~M) produced a concentration-dependent co raction of 
the small mesenteric artery. The selective prostanoid TP receptor antagonist, SQ 30,741 ([1S-[lct,2ct(5Z),3a,4a]]-7- 
[[[[[(•xahepty•)amin•]acety•]amin•]-methy•]-7-•xabicyc••[2.2.•]hept-2-y•]-5-hepten•ic acid; 1 /xM),produced aparallel, rightward shift of 
the U46619 curve with an associated pA 2 value of 7.43 + 0.09. Treatment of tissues with 100/xM benextramine d pressed the maximum 
response to U46619 in a time-dependent manner. However, neither SQ 30,741 (10 tzM) nor U46619 (10 /zM) incubation significantly 
protected against his effect. Thus, benextramine acts as an irreversible noncompetitive antagonist of U46619. The mechanism of this 
action is not yet clear. 
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1. Introduction 2. Materials and methods 
The tetramine disulphide, benextramine, has previously 
been classified and employed as an irreversible competi- 
tive antagonist of a-adrenoceptors (Melchiorre, 1981) and 
neuropeptide Y receptors (Tessel et al., 1993; Palea et al., 
1995). In this study, we investigated the effects of benex- 
tramine on the response of the rat isolated small mesen- 
teric artery to the 9,11-methanoepoxy analogue of prosta- 
glandin H 2 , U46619, which is believed to mediate contrac- 
tion of vascular smooth muscle via a selective action at 
prostanoid TP receptors (Coleman et al., 1994). We show 
that benextramine acts as an irreversible antagonist of 
U46619 in the small mesenteric artery via an, as yet 
unknown, nonsyntopic mechanism. 
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2.1. Rat isolated small mesenteric artery preparation 
Male Wistar rats (225-350 g) were killed by cervical 
dislocation and the mesentery was removed and placed in 
ice-cold modified Krebs-Henseleit solution of the follow- 
ing composition (mM): NaC1 119.0, NaHCO 3 25.0, KCI 
4.7, KH2PO 4 1.2, MgSO 4 1.2, glucose 5.5, CaC12 2.5 and 
ethylenediaminetetra-acetic acid 0.026. Four arterial trees 
were dissected from each mesenteric vascular bed and 
were cleared of surrounding adipose tissue. From each 
arterial tree, a ~ 2 mm ring segment was mounted in a 
small vessel myograph (J.P. Trading, Aarhus, Denmark) 
with separated 6 ml organ baths (thermostatically con- 
trolled at 37 + 0.5°C, containing modified Krebs-Henseleit 
solution and continuously gassed with 95% 0 2 and 5% 
CO 2) as described by Mulvany and Halpern (1977). The 
endothelium was removed by gentle rubbing of the intimal 
surface with a scoured whisker from a cat (Wang et al., 
1994). Tissue responses were measured continuously as 
changes in isometric tension and were displayed on poten- 
tiometric hart recorders. 
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2.2. Experimental protocol 3. Results 
Following a 30 min stabilization period, the internal 
diameter of each vessel was set to a tension equivalent to 
0.9 times the estimated iameter at 100 mm Hg effective 
transmural pressure (ll00:183 _+ 7 /zm, n = 43) according 
to the standard procedure of Mulvany and Halpern (1977). 
After a further 30 min stabilization period, a calibration 
contraction (6.6 _+ 0.5 mN) was obtained to 30/~M 5-hy- 
droxytryptamine (5-HT) in each tissue and the absence of 
the endothelium was then confirmed by the lack of a 
response to 10 /xM of the muscarinic acetylcholine r cep- 
tor agonist, 5-methylfurmethide. 
In the first experiment, following a washout period of 
15 min, the tissues were incubated for 60 min with 3 /zM 
indomethacin to prevent synthesis of endogenous 
prostanoids and with 1 /zM SQ 30,741 or vehicle. Single 
U46619 concentration-effect (E/[A]) curves were then 
obtained by cumulative additions as third-log unit concen- 
tration increments. Effect was expressed as percentage of 
the calibration response to 30 /xM 5-HT. 
In the second series of experiments, the tissues were 
exposed to 100/xM benextramine or vehicle for 30, 60 or 
120 min and were subsequently washed for 30 min with 
ten solution changes. Following 60 min incubation with 3 
/.tM indomethacin, U46619 E/[A] curves were obtained as 
described above. It was also investigated whether SQ 
30,741 or U46619 could protect against he antagonistic 
action of benextramine. For this purpose, the same proto- 
col as described above was employed, but the tissues were 
incubated until a response plateau was achieved with 10 
/xM SQ 30,741 (30 min) or with 10/~M U46619, before 
exposing the tissue to benextramine (100 /zM, 30 min) 
without washing SQ 30,741 or U46619. Preliminary exper- 
iments had shown that incubation with SQ 30,741 or 
U46619 alone (i.e. not followed by benextramine treat- 
ment) had no significant effect on the U46619 E/[A] 
curve (data not shown). 
2.3. Compounds 
The following compounds, obtained from the sources 
mentioned, were used: [ArgS]vasopressin (acetate salt), 
benextramine tetrahydrochloride, 5-hydroxytryptamine cre-
atine sulphate (5-HT), indomethacin and U46619 
(11 a,9a-epoxymethano- 15S-hydroxy-prosta-5Z, 13 E-
dienoic acid): Sigma Chemical Company, Netherlands; 
5-methylfurmethide iodide: Wellcome Research Laborato- 
ries, UK; SQ 30,741 ([1 S-[1 a,2 a (5Z),3 a Act ]]-7-[[[[[(oxa- 
heptyl)amino]acetyl]amino]-methyl]-7-oxabicyclo[2.2.1 ]- 
hept-2-yl]-5-heptenoic acid): Bristol-Myers Squibb, Prince- 
ton, NJ, USA. Indomethacin and SQ 30,741 were dis- 
solved in absolute thanol. U46619 was dissolved initially 
in 20% ethanol to give a 1 mM stock solution and subse- 
quently diluted in distilled water. All other drugs were 
dissolved in distilled water. 
3.1. Interaction between U46619 and SQ 30,741 
U46619 (10 nM- 10/xM) produced a concentration-de- 
pendent contraction of the small mesenteric artery (Fig. 1) 
and the individual E/[A] curve data (n = 5) were fitted to 
the Hill equation (see Jenkinson et al., 1995) to provide 
estimates of midpoint location (p[A]50:7.38 + 0.06), mid- 
point slope (nn: 1.5 + 0.1) and upper asymptote (a: 107 
+ 6%). SQ 30,741 (1 ~M) produced a parallel rightward 
shift of the U46619 E/[A] curve without significantly 
changing the Hill slope or maximum response (p[A]50: 
5.93__+0.09; nil: 1.7+0.2; a: 107_7%; n=5)  and a 
pA z value of 7.43 ___ 0.09 was estimated, indicative of an 
action at prostanoid TP receptors (see Schumacher t al., 
1989; Ogletree and Allen, 1992). 
3.2. Effect of benextramine on the U46619-induced con- 
traction 
Treatment with 100/xM benextramine for 30, 60 or 120 
min, followed by washout, depressed the maximum re- 
sponse to U46619 in a time-dependent manner (Fig. 2). In 
an attempt to clarify the mechanism behind this action, we 
investigated whether incubation with either SQ 30,741 or 
U46619 could protect, without subsequent washing, against 
the antagonistic effect of benextramine. As shown in Fig. 
2, prior incubation of the tissues with neither SQ 30,741 
(10/zM, 30 min) nor U46619 (10 /zM, incubated until a 
response plateau was achieved) produced any significant 
protection against he effect of subsequent exposure for 30 
min to 100 /zM benextramine. 
Treatment (30 min) with 100/xM benextramine had no 
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Fig. 1. Concentration-effect curves obtained with the rat isolated small 
mesenteric artery for U46619 in the absence (0 )  and presence (O)  of 1 
/xM SQ 30,741. The lines shown superimposed on the mean experimental 
data points (n = 5) were simulated using the Hill equation (see text for 
parameter estimates). Horizontal and vertical error (S.E.M.) bars are 
shown on the mean midpoint and upper asymptote locations, respectively. 
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Fig. 2. Concentration-effect curves (n= 4-6) obtained with the rat 
isolated small mesenteric artery for U46619 following treatment with 
vehicle (O), 100 /xM benextramine alone for 30 (©), 60 (l l)  and 120 
min (El) or 100/xM benextramine for 30 min in the presence of 10/xM 
SQ 30,741 (,~) and 10 /.tM (z~) U46619. Error bars indicate S.E.M. 
significant effect on the Hill equation parameter stimates 
(p[A]50:8.98 + 0.14 and 8.91 + 0.09; nil: 2.6 + 0.6 and 
2.1 +0.1; a: 129_+4% and 116+ 14% for control and 
benextramine-treated tissues, respectively, n = 3) associ- 
ated with the E/[A] curves of another contractile agent in 
this assay, arginine vasopressin (0.1-100 nM). Thus, the 
antagonism of U46619 by benextramine appeared not to be 
due to a nonspecific effect. 
4. Discussion 
In this study, we have investigated the effects of benex- 
tramine, a ligand previously classified and employed as an 
irreversible competitive antagonist of a-adrenoceptors 
(Melchiorre, 1981) and neuropeptide Y receptors (Tessel et 
al., 1993; Palea et al., 1995), on the U46619-mediated 
contraction of the rat small mesenteric artery. Previous 
studies have shown that, in a variety of assays, U46619 
mediates vasoconstriction via a selective action at 
prostanoid TP receptors (see Ogletree and Allen, 1992; 
Coleman et al., 1994; Baxter et al., 1995). This also 
appears to be the case in the rat isolated small mesenteric 
artery preparation, since the pA 2 estimate of 7.4 obtained 
for SQ 30,741 was similar to previously reported affinity 
values for prostanoid TP receptors in various rat smooth 
muscle assays (pKB: ~ 7.8; Ogletree and Allen, 1992) and 
human and monkey platelets (pKB: 7.1 and 7.2, respec- 
tively; Schumacher t al., 1989). 
Treatment of small mesenteric arteries with benex- 
tramine was found to produce significant inhibition of the 
response to U46619. The degree of this effect was time 
dependent, i.e. the longer the incubation with benex- 
tramine, the greater the magnitude of the antagonism, 
indicative of an irreversible antagonistic mechanism 
(Furchgott, 1954, 1966; Palea et al., 1995). In an attempt 
to elucidate the underlying mechanism of the antagonistic 
effect of benextramine, we performed receptor protection 
experiments, ince it would be expected that if an irre- 
versible antagonist inhibits the response of an agonist by 
reducing the number of receptors, then a reversible com- 
petitive antagonist hould be able to protect receptors from 
such inactivation (Furchgott, 1954, 1966). However, SQ 
30,741, in a concentration of 10 /zM, which was ~ 250 
times its apparent affinity for prostanoid TP receptors in 
the small mesenteric artery and thus would be expected to 
leave less than 0.5% of the receptors unoccupied, id not 
produce significant protection against he effects of benex- 
tramine treatment. Similarly, incubation with a near-maxi- 
mally effective concentration (10/zM) of U46619 did not 
significantly inhibit the effects of benextramine. Hence, 
the protection experiments suggest that benextramine does 
not bind to the same site on the receptor as U46619 and 
SQ 30,741, but acts as an irreversible noncompetitive 
antagonist (see Jenkinson et al., 1995) of the prostanoid TP 
receptor-mediated contraction of the rat small mesenteric 
artery. Therefore, benextramine cannot be used as a tool to 
determine dissociation equilibrium constants for agonists 
at prostanoid TP receptors in a manner similar to that 
described previously for al-adrenoceptors (see, for exam- 
ple, Elliot and Pearce, 1994) and neuropeptide Y Yl 
receptors (Palea et al., 1995). 
At present, we do not know the underlying mechanism 
of the antagonistic action of benextramine exposed in this 
study. The response to arginine vasopressin was not af- 
fected by benextramine, thus a nonspecific effect can be 
ruled out. Furthermore, vasopressin V 1 receptors, which 
are believed to mediate vasoconstriction to arginine vaso- 
pressin (Thibonnier, 1992), are coupled to the same signal 
transduction system as prostanoid TP receptors, namely the 
production of inositol-l,4,5-triphosphate (IP3; Thibonnier, 
1992; Coleman et al., 1994). This suggests that the antago- 
nism was not due to a direct effect at the IP 3 pathway. 
Previously, it has been reported that benextramine is a 
blocker of calcium channels in rat brain with an associated 
IC50 value of ~ 10 /xM (Plotek and Atlas, 1983). How- 
ever, this effect was shown to be reversible (Plotek and 
Atlas, 1983) and thus cannot explain our data. 
Overall, it remains to be clarified whether benextramine 
interferes with the effector pathway following prostanoid 
TP receptor activation by U46619 or whether it reduces 
agonist affinity and/or efficacy via an action at an al- 
losteric receptor site. 
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